Quantcast
Last updated on April 16, 2014 at 11:09 EDT

Alonso Krangle LLP Files NuvaRing Blood Clot Lawsuit on Behalf of a Young Woman Who Suffered Deep Vein Thrombosis While Using NuvaRing Contraceptive Device

September 24, 2012

NuvaRing Lawsuit Alleges Merck & Co., Organon USA, Inc., and other Defendants Failed to Warn Plaintiff of Serious NuvaRing Side Effects, Including a Higher Risk of Clots, Such as Deep Vein Thrombosis and Pulmonary Embolism, Compared to Birth Control Pills.

Mellville, New York (PRWEB) September 24, 2012

Alonso Krangle LLP, an national law firm focused on fighting for the rights of serious personal injury victims of harmful drug side effects, announce they have filed a NuvaRing side effect lawsuit on behalf of a young woman who suffered a deep vein thrombosis while using the NuvaRing contraceptive device. The Nuvaring side effect lawsuit, which was filed on September 18, 2012, in New Jersey Superior Court, Bergen County, names Merck & Co. Organon USA, Inc., Organon Pharmaceuticals USA, Inc., N.V. Organon, Schering Plough Corporation and Akzo Nobel, NV as Defendants. (BER-L-007242-12)

Alonso Krangle is currently offering FREE NuvaRing lawsuit consultations to victims of alleged NuvaRing side effects, including:

  •     Venous Thromboembolism (Blood Clots)
  •     Deep vein thrombosis
  •     Pulmonary embolism
  •     Strokes
  •     Wrongful death

To discuss a potential claim with one of the experienced and compassionate NuvaRing side effect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

According to the complaint, the Plaintiff, a woman from Picayune, Mississippi, suffered a deep vein thrombosis, a serious, life-threatening type of blood clot in or about September 2010, while using NuvaRing. The contraceptive device is marketed as the first and only, once-a-month vaginal birth control ring, and is touted as being as effective at preventing pregnancy as other hormonal birth control methods, including birth control pills, but with more convenience because it offers “month long protection.” The package insert accompanying NuvaRing stated that the vaginal ring is expected to be associated with similar risks to that of birth control pills. However, the lawsuit alleges that the NuvaRing package insert is misleading because the safety information provided to consumers was derived primarily from studies of birth control pills, and not primarily from studies of NuvaRing.

Among other things, the complaint alleges that the Defendants failed to warn of the extent of venous thromboembolism, including pulmonary embolism and deep vein thrombosis, associated with NuvaRing. Further, the lawsuit asserts that etonogestral, a synthetic, third generation progestin, which is used as a starter in NuvaRing, was not the subject of sufficient and adequate testing, and that the Defendants knew or should have known that information conveying certain adverse events, including deep vein thrombosis, pulmonary embolism, and death, should have been set forth in NuvaRing´s package insert.

A number of studies have found an association between NuvaRing and serious side effects, including blood clots, deep vein thrombosis, pulmonary embolism, heart attacks and stroke. Research published in The New England Journal of Medicine in June found that women who used combined hormonal devices, such as NuvaRing, were 2.5 to 3 times more likely to experience heart attacks and strokes compared to women who used other types of hormonal birth control. A study published the month prior in the British Medical Journal found the likelihood of NuvaRing users experiencing a dangerous blood clot was 90% higher among users of the vaginal ring than it was for women taking combined oral contraceptives containing levonorgestrel.

[nejm.org/doi/full/10.1056/NEJMoa1111840?query=featured_home]

[bmj.com/content/344/bmj.e2990]

Last October, results from an FDA-funded study that involved 800,000 American women using some form birth control between 2001 and 2008 revealed using NuvaRing increased the risk of blood clots, including deep vein thrombosis and pulmonary embolism, by 56% in comparison to older birth control pills. The FDA study noted that combined hormonal contraceptives, including the etonogestrel/ethinyl estradiol vaginal ring, “potentially result in higher sustained exposure to estrogen and hence, increased thromboembolic risk.” [fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf]

Over 125 NuvaRing lawsuits are pending in New Jersey Superior Court, Bergen County, in a Mass Tort proceeding. Nine NuvaRing lawsuits have been selected for the litigation´s bellwether trials, scheduled to begin on February 4, 2013. The New Jersey NuvaRing trials will be the first to test Plaintiffs´ claims that NuvaRing is more likely to cause deadly blood clots, heart attacks and strokes than other forms of hormonal birth control. (Docket No. BER-L-3081-09)

More than 800 additional NuvaRing lawsuits are pending in a federal litigation underway in U.S. District Court, Eastern District of Missouri (MDL No. 1964). The first trial in the federal litigation has been scheduled for May 6, 2013.

There is still time for young women who may have been injured by NuvaRing, or their families, to file personal injury lawsuits seeking compensation for medical bills, pain and suffering, emotional distress and other damages. To discuss a potential claim with one of the experienced and compassionate NuvaRing side effect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

About Alonso Krangle LLP

Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical malpractice, whistleblower actions and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

Contact:

Alonso Krangle LLP

445 Broad Hollow Road

Suite 205

Melville, New York 11747

Toll-FREE 1-800-403-6191

Tel: 516-350-5555

Fax: 516-350-5554

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9932118.htm


Source: prweb